Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-203: Enfortumab Vedotin in Chinese Patients With Previously Treated Advanced Urothelial Cancer
NCT04995419Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in urothelial carcinoma (UC), sponsored by Astellas Pharma. Primary endpoints: Objective Response Rate up to 9.33 months, Maximum Concentration and 7 more. Started Jul 2021; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04995419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995419.